Aligos Therapeutics’ HERALD Study Shows Promising MASH Treatment Results, Yet Fails to Impress Investors

Study Results:
Aligos Therapeutics announced positive topline results from its Phase 2a HERALD study for ALG-055009, a thyroid hormone receptor beta agonist aimed at treating metabolic-dysfunction-associated steatohepatitis (MASH).

Efficacy:
The study demonstrated significant reductions in liver fat and improvements in other clinically relevant biomarkers, such as lipoprotein (a), indicating the drug's potential as a best-in-class treatment.

Tolerability:
ALG-055009 showed a favorable tolerability profile, which is crucial for MASH medications that are likely to be administered for prolonged periods.

Investor Reaction:
Despite the promising results, Aligos' stock price fell, indicating that investors were not impressed by the data.

Future Plans:
Aligos is in early discussions with potential partners to fund the continued development of ALG-055009 and plans to complete the activities required for a Phase 2b study by mid-2025.